Trial Profile
Observational study on the change of clonal heterogeneity by afatinib or gefitinib treatment using next generation sequencing analysis and the effect of osimertinib as a secondary treatment (CHASE study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Gefitinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CHASE study
- 02 Sep 2022 Status changed from active, no longer recruiting to completed.
- 01 Sep 2020 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2019 Status changed from not yet recruiting to recruiting.